Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Vitale

Showing results (111-120 of 219) with videos related to

Pageof 22
Sort By:
Clinical Rheumatology|August 13, 2018
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patientsClaudia Fabiani, Antonio Vitale, Donato Rigante, et al.
Mediators of Inflammation|August 19, 2014
Untangling the web of systemic autoinflammatory diseasesDonato Rigante, Giuseppe Lopalco, Antonio Vitale, et al.
Clinical Rheumatology|May 17, 2018
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapiesClaudia Fabiani, Jurgen Sota, Donato Rigante, et al.
Vaccines|April 23, 2025
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung CancerEmanuele Vita, Federico Monaca, Luca Mastrantoni, et al.
Clinical Rheumatology|March 25, 2014
Serum amyloid-A in Behçet's diseaseAntonio Vitale, Donato Rigante, Giuseppe Lopalco, et al.
Clinical and Experimental Rheumatology|April 4, 2019
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitisGian Marco Tosi, Jurgen Sota, Antonio Vitale, et al.
International Journal of Molecular Sciences|April 20, 2019
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory DiseasesAlessandra Bettiol, Giuseppe Lopalco, Giacomo Emmi, et al.
Frontiers in Oncology|July 30, 2025
Enhanced response to dabrafenib plus trametinib in a patient with <i>BRAF</i> <sup>V600E</sup> lung cancer harboring an <i>RNF43</i> variant of unknown significance: a case reportEttore D'Argento, Antonio Vitale, Jacopo Russo, et al.
Journal of Clinical Medicine|January 21, 2023
From Bench to Bedside in Rheumatoid Arthritis from the "2022 GISEA International Symposium"Antonio Vitale, Stefano Alivernini, Roberto Caporali, et al.
Frontiers in Oncology|January 10, 2022
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old FailuresMiriam Grazia Ferrara, Alessio Stefani, Sara Pilotto, et al.
Pageof 22

Showing results (111-120 of 219) with videos related to

Sort By:
Pageof 22
Clinical Rheumatology|August 13, 2018
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patientsClaudia Fabiani, Antonio Vitale, Donato Rigante, et al.
Mediators of Inflammation|August 19, 2014
Untangling the web of systemic autoinflammatory diseasesDonato Rigante, Giuseppe Lopalco, Antonio Vitale, et al.
Clinical Rheumatology|May 17, 2018
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapiesClaudia Fabiani, Jurgen Sota, Donato Rigante, et al.
Vaccines|April 23, 2025
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung CancerEmanuele Vita, Federico Monaca, Luca Mastrantoni, et al.
Clinical Rheumatology|March 25, 2014
Serum amyloid-A in Behçet's diseaseAntonio Vitale, Donato Rigante, Giuseppe Lopalco, et al.
Clinical and Experimental Rheumatology|April 4, 2019
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitisGian Marco Tosi, Jurgen Sota, Antonio Vitale, et al.
International Journal of Molecular Sciences|April 20, 2019
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory DiseasesAlessandra Bettiol, Giuseppe Lopalco, Giacomo Emmi, et al.
Frontiers in Oncology|July 30, 2025
Enhanced response to dabrafenib plus trametinib in a patient with <i>BRAF</i> <sup>V600E</sup> lung cancer harboring an <i>RNF43</i> variant of unknown significance: a case reportEttore D'Argento, Antonio Vitale, Jacopo Russo, et al.
Journal of Clinical Medicine|January 21, 2023
From Bench to Bedside in Rheumatoid Arthritis from the "2022 GISEA International Symposium"Antonio Vitale, Stefano Alivernini, Roberto Caporali, et al.
Frontiers in Oncology|January 10, 2022
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old FailuresMiriam Grazia Ferrara, Alessio Stefani, Sara Pilotto, et al.
Pageof 22